Skip to main content
. 2019 Apr 17;17(5):503–516. doi: 10.1111/ddg.13834

Figure 1.

Figure 1

Cumulative probability of drug survival of non‐biological (a) and biological therapy (b) in the PPP cohort based on the number of treatment courses (Kaplan‐Meier analysis).

Abbr.: ACI, acitretin; MTX, methotrexate; FAE, fumaric acid esters; CyA, cyclosporine A; ALI, alitretinoin; APR, apremilast; ADA, adalimumab; ETA, etanercept; INX, infliximab; GOL, golimumab; CER, certolizumab pegol; UST, ustekinumab; SEC, secukinumab.